Naramig (Naratriptan)

Naratriptan works by stimulating 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This causes vasoconstriction of dilated vessels and blocks the release of inflammatory neuropeptides, interrupting the migraine cascade and reducing pain.

The appropriate dose of Naramig is determined by the prescribing healthcare professional based on individual patient factors. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

The safety of naratriptan in pregnancy and lactation has not been established. Healthcare providers should assess the potential benefits against possible risks before prescribing Naramig to pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Naramig (naratriptan) is a selective serotonin 5‑HT1 receptor agonist, similar to other triptans such as sumatriptan or rizatriptan. Compared with some alternatives, naratriptan has a longer half‑life, which may provide sustained relief with fewer doses, but individual response varies.

Naramig should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Naramig is taken orally, usually as a tablet, at the first sign of a migraine attack. It should be swallowed with water and not crushed or chewed. Patients should follow the dosing instructions provided by their prescriber.

Serious risks include chest pain or tightness, arrhythmias, severe hypertension, serotonin syndrome, and rare ischemic events such as stroke or myocardial infarction. Patients experiencing any of these symptoms should seek immediate medical attention.

Naramig is contraindicated in patients with uncontrolled hypertension, known coronary artery disease, history of stroke or transient ischemic attack, and those taking MAO inhibitors or other serotonergic agents. It should also be avoided in individuals with known hypersensitivity to naratriptan.